Home Cart Sign in  
Chemical Structure| 162271-52-5 Chemical Structure| 162271-52-5

Structure of Gastrin/CCK antagonist 1
CAS No.: 162271-52-5

Chemical Structure| 162271-52-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Wang, Cheng-xiang ; Wang, Ting-ting ; Zhang, Kun-dong ; Li, Ming-yu ; Shen, Qian-cheng ; Lu, Shao-yong , et al.

Abstract: Pancreatic ductal adenocarcinoma (PDAC) is currently one of the most lethal cancers worldwide. Several basic studies have confirmed that Kirsten rat sarcoma virus (KRAS) is a key driver gene for the occurrence of PDAC, and KRAS mutations have also been found in most patients in clinical studies. In this study, two pan-KRAS inhibitors, BI-2852 and BAY-293, were chosen as chemical probes to investigate their antitumor potency in PDAC. Their inhibitory effects on KRAS activation were validated in vitro and their antiproliferative potency in PDAC cell lines were profiled, with half-maximal inhibitory concentration (IC50) values of approximately 1 μM, demonstrating the therapeutic potential of pan-KRAS inhibitors in the treatment of PDAC. However, feedback regulation in the KRAS pathway weakened inhibitor activity, which was observed by a 50 times difference in BAY-293 from in vitro activity. Furthermore, pan-KRAS inhibitors effectively inhibited cell proliferation in 3D organoids cultured from PDAC patient samples; however, there were some variations between individuals. These results provide a sufficient theoretical foundation for KRAS as a clinical therapeutic target and for the application of pan-KRAS inhibitors in the treatment of PDAC, with important scientific significance in translational medicine.

Keywords: pancreatic ductal adenocarcinoma ; KRAS ; driver gene ; BAY-293 ; organoid

Purchased from AmBeed: ; ; ;

Alternative Products

Product Details of Gastrin/CCK antagonist 1

CAS No. :162271-52-5
Formula : C28H32FN5O4
M.W : 521.58
SMILES Code : O=C1C(NC(NC2=CC=C(F)C=C2)=O)C(N(CC(N3CCCC3)=O)C4=CC=CC=C4N1C5CCCCC5)=O

Safety of Gastrin/CCK antagonist 1

Related Pathways of Gastrin/CCK antagonist 1

GPCR

Isoform Comparison

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.92mL

0.38mL

0.19mL

9.59mL

1.92mL

0.96mL

19.17mL

3.83mL

1.92mL

 

Historical Records

Categories